Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
For many people, injection needles can be scary – and the larger ones for specialized longer-term medications are far more ...
Theratechnologies (THTX) announced that the FDA has approved the Company’s supplemental Biologics License Application, or sBLA, for the F8 ...
Shares of Theratechnologies (NASDAQ:THTX) spiked on Wednesday after the FDA approved a new formulation of its bestselling ...
People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...
New, improved formulation set to replace EGRIFTA SV®MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or ...
When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback